Exclusive speaker interview with SCHOTT Pharmaceutical Systems released for Pre-Filled Syringes East Coast 2019

SMi Group8 - 9 April 2019, Boston, USA.
The 6th Annual Pre-Filled Syringes East Coast conference is returning to Boston, USA. The two-day event will bring together specialists within the industry to provide an exclusive insight into the sphere of regulation, new digital technology trends, human studies and innovative design and delivery systems within the prefilled syringe industry.

In the run up to the conference, SMi Group caught up with Patrick Gallagher, Business Development Manager, SCHOTT Pharmaceutical Systems, to discuss his upcoming presentation, and his thoughts on the current challenges and opportunities in the pre-filled syringes field.

A snapshot of Patrick Gallagher's interview

Q: The Pre-Filled Syringes market has matured greatly over recent years, what key differences have you noticed in the last year regarding significant developments? A: "In recent years, we have seen quite a bit of interest from pharmaceutical companies to differentiate through delivery device, whether through lifecycle management of a biologic drug into a more complex device or by converting a legacy drug from vial to pre-filled syringe. PFS and cartridge-based primary containers can improve patient safety through less dose preparation and greater ease of use, as well as facilitate the transition of drug administration from a hospital to homecare setting, thus improving patient outcomes."

Q: What do you see as the greatest challenge for you to overcome personally in the pre-filled syringes field at the moment? A: "As an industry, we are still in the early stages of developing connected health solutions and while we are starting to generate significant data it will take some time to best realize how to use this data. Pharma and Medtech companies will need to continue to educate key healthcare stakeholders that device-generated data can improve patient outcomes and drive down healthcare costs."

The full speaker interview and more content including the latest brochure, past attendees list, and other exclusive speaker interviews can be found on the DOWNLOADS section on the website at http://www.pfsamericas.com/pr7

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

Novartis signs initial agreement to reserve capaci…

Novartis has signed an initial agreement with Roche to reserve capacity and implement the technology transfer for the production of the active pharmaceutical ingredient (...

Pfizer acquires Amplyx Pharmaceuticals

Pfizer Inc. (NYSE: PFE) announced today that it has acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilita...

Moderna announces additional investments to increa…

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced it is making new funding commitments to i...

Moderna announces emergency use listing granted by…

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the World Health Organization (WHO) has is...

Sanofi to help manufacture Moderna COVID-19 vaccin…

Sanofi has entered into an agreement with Moderna, under which Sanofi will help manufacture Moderna's COVID-19 vaccine, supporting the COVID-19 pandemic and vaccine suppl...

Valneva switches focus to bilateral discussions to…

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical n...

Speeding new treatments

A year into the COVID-19 pandemic, mass vaccinations have begun to raise the tantalizing prospect of herd immunity that eventually curtails or halts the spread of SARS-Co...

Pfizer and BioNTech to supply the European Union w…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced they will supply an additional 100 million doses of COMIRNATY®, the companies' COVID-19 vaccine, to the 2...

Brazilian coronavirus variant likely to be more tr…

Even though more and more vaccines against the coronavirus are being administered all over the world, many countries are still battling with outbreaks and face difficulti...

Patients who are obese or overweight are at risk f…

COVID-19 patients who are overweight or obese are more likely to develop a more severe infection than patients of healthy weight, and they require oxygen and invasive mec...

Updated results on coronavirus vaccination effecti…

Several weeks following the publication of the large real-world COVID-19 vaccine effectiveness study by the Clalit Research Institute in Collaboration with Harvard Univer...

Our immune systems blanket the SARS-CoV-2 spike pr…

The most complete picture yet is coming into focus of how antibodies produced in people who effectively fight off SARS-CoV-2 work to neutralize the part of the virus resp...